DESCRIPTION

According to the WHO, 170 million people, or 3% of the world's population, are infected with Hepatitis C and at risk of developing liver cirrhosis and/or liver cancer. 3-4 million people each year are newly diagnosed carriers of the virus.

**Advanced Therapy for Hepatitis C Infection** provides you with expert guidance from the world’s leading hepatologists on the very latest treatment options for patients with the HCV virus. Focusing mainly on the efficacy and clinical use of antiviral therapies, key topics include:

- Treatment of recurrent hepatitis C following liver transplantation
- Antivirals in Cirrhosis and Portal Hypertension
- HIV and Hepatitis C co-infection
- Cytopenias: how they limit therapy and potential correction
- The problem of insulin resistance and its effect on therapy
Antivirals in Acute Hepatitis C

In addition, it fully covers the foundations for understanding antiviral therapies in HCV, such as the complex pharmacology and mechanisms of antiviral drugs. Finally, a chapter on New Horizons: *Interleukin 28 and direct-acting antiviral therapy for HCV*, offers you a glimpse into the future possibilities for HCV therapy.

Edited by a team of outstanding international reputation, *Advanced Therapy for Hepatitis C Infection* is an essential tool for all hepatologists and gastroenterologists involved in the management of patients with Hepatitis C.

ABOUT THE AUTHOR

**Professor Geoff McCaughan** is Director of the AW Morrow Liver Centre and Physician in Charge at the Australian National Liver Transplant Unit.

**John McHutchison** is a professor of medicine at Duke University Medical Center, and since 2002, Director of the DCRI’s Gastroenterology and Hepatology Research division.

For additional product details, please visit [https://www.wiley.com/en-us](https://www.wiley.com/en-us)